Methergine label

Methergine

Methergine Recall

Get an alert when a recall is issued.

Add Info

Side Effects & Adverse Reactions

This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, Methergine® (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.

Add Info

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Add Info

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

Add Info

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Add Info

Uses

For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder.

Add Info

History

There is currently no drug history available for this drug.

Add Info

Other Information

Methergine® (methylergonovine malate) is a semi-synthetic ergot alkaloid used for the

prevention and control of postpartum hemorrhage.

Methergine Tablets are for oral ingestion containing 0.2mg of methylergonovine maleate.

Active ingredient

methylergonovine maleate, USP, 0.2mg.

Inactive Ingredients

Acacia, carnauba wax, gelatin special, D and C Red #7, FD and C Blue #1,

lactose, maleic acid, mixed parabens, povidone, sodium benzoate, sodium hydroxide,

starch, stearic acid, sucrose, talc, and titanium dioxide.

Its structural formula is

image of structural formula

Add Info
Add to My Alerts
Report Side Effect
Leave a Review
Navigate to :
Methergine Recall
Side Effects & Adverse Reactions
Legal Issues
FDA Safety Alerts
Manufacturer Warnings
FDA Labeling Changes
Uses
History
Other Information
Manufacturers
Trending Topics

Methergine Manufacturers

  • Apotheca, Inc.
    Methergine | Apotheca, Inc.
    No Recall

    Methergine | Apotheca, Inc.

    Methergine | Apotheca, Inc.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

    Orally

    One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

  • Pd-rx Pharmaceuticals, Inc.
    Methergine | Pd-rx Pharmaceuticals, Inc.
    No Recall

    Methergine | Pd-rx Pharmaceuticals, Inc.

    Methergine | Pd-rx Pharmaceuticals, Inc.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

    Intramuscularly

    1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.

    Intravenously

    Dosage same as intramuscular. (See WARNINGS.)

    Orally

    One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

  • Dispensing Solutions, Inc.
    Methergine | Dispensing Solutions, Inc.
    No Recall

    Methergine | Dispensing Solutions, Inc.

    Methergine | Dispensing Solutions, Inc.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

    Intramuscularly

    1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.

    Intravenously

    Dosage same as intramuscular. (See WARNINGS.)

    Orally

    One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

  • Pd-rx Pharmaceuticals, Inc.
    Methergine | Pd-rx Pharmaceuticals, Inc.
    No Recall

    Methergine | Pd-rx Pharmaceuticals, Inc.

    Methergine | Pd-rx Pharmaceuticals, Inc.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

    Intramuscularly

    1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.

    Intravenously

    Dosage same as intramuscular. (See WARNINGS.)

    Orally

    One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

  • Bryant Ranch Prepack
    Methergine | Bryant Ranch Prepack
    No Recall

    Methergine | Bryant Ranch Prepack

    Methergine | Bryant Ranch Prepack

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

    Intramuscularly

    1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.

    Intravenously

    1 mL, 0.2 mg, administered slowly over a period of no less than 60 seconds (See WARNINGS.)

    Orally

    One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

  • Novartis Pharmaceuticals Corporation
    Methergine | Novartis Pharmaceuticals Corporation
    No Recall

    Methergine | Novartis Pharmaceuticals Corporation

    Methergine | Novartis Pharmaceuticals Corporation

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.

    Intramuscularly

    1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.

    Intravenously

    1 mL, 0.2 mg, administered slowly over a period of no less than 60 seconds (See WARNINGS.)

    Orally

    One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

Login To Your Free Account